Meeting
2019 ASCO Annual Meeting
Exploratory analysis of the effect of maintenance rucaparib on postprogression outcomes in patients (pts) with platinum-sensitive recurrent ovarian carcinoma (OC) and updated safety data from the phase 3 study ARIEL3.
Authors
Robert L. Coleman
The University of Texas MD Anderson Cancer Center, Houston, TX
Robert L. Coleman , Amit M. Oza , Domenica Lorusso , Carol Aghajanian , Ana Oaknin , Andrew Peter Dean , Nicoletta Colombo , Johanne I Weberpals , Andrew R. Clamp , Giovanni Scambia , Alexandra Leary , Robert W. Holloway , Margarita Amenedo , Peter C.C. Fong , Jeffrey C. Goh , David M. O'Malley , Teresa Cameron , Lara Maloney , Sandra Goble , Jonathan A. Ledermann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01968213
Citation
J Clin Oncol 37, 2019 (suppl; abstr 5522)
DOI
10.1200/JCO.2019.37.15_suppl.5522
Abstract #
5522
Poster Bd #
345
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study.
First Author: Carol Aghajanian
Poster
2022 ASCO Annual Meeting
Efficacy and safety of rucaparib maintenance treatment in patients from ARIEL3 with platinum-sensitive, recurrent ovarian carcinoma not associated with homologous recombination deficiency.
First Author: Robert L. Coleman
Poster
2018 ASCO Annual Meeting
Exploratory analysis of percentage of genomic loss of heterozygosity (LOH) in patients with platinum-sensitive recurrent ovarian carcinoma (rOC) in ARIEL3.
First Author: Ana Oaknin
Poster
2012 ASCO Annual Meeting
An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer.
First Author: Carol Aghajanian